(Q37999566)

26 August 2017

title

Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis (English)

1 reference

26 August 2017

John Cookson

1

1 reference

26 August 2017

Richard Hodgson

series ordinal

2

1 reference

26 August 2017

Hiram J Wildgust

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

2 April 2012

1 reference

Journal of Psychopharmacology

26 August 2017

published in

1 reference

26 August 2017

volume

26

1 reference

26 August 2017

issue

5 Suppl

1 reference

26 August 2017

page(s)

42-51

1 reference

Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Prolactin elevation with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Hyperprolactinaemia in early psychosis-not only due to antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Antipsychotic drugs and obesity: is prolactin involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Pituitary volume increase during emerging psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Oestrogens, Dopamine and Mood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Prolactin shifts after neuroleptic withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

White matter plasticity and enhanced remyelination in the maternal CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Prolactin Responses to Neuroleptics in Normal and Schizophrenic Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Adverse effects of prolactin in rodents and humans: breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Risk of hip fracture in patients with a history of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

A study of serum prolactin levels in schizophrenia: comparison of males and females

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: neuroendocrine studies in normal men

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Prolactin and smoking status in antipsychotic-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Hyperprolactinemia and prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Change in sexual dysfunction with aripiprazole: a switching or add-on study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

The effect of atypical antipsychotic agents on prolactin levels in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Antipsychotics and hyperprolactinaemia: clinical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Sulpiride: Assessment of a pharmacologically and chemically distinct neuroleptic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Serotonin rising--the bone, brain, bowel connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Examining the dopamine hypotheses of schizophrenia and of mania using the prolactin response to antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

No stress please! Mechanisms of stress hyporesponsiveness of the maternal brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

The impact of hyperprolactinaemia on sexual function in patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Early normalization of luteinizing hormone pulsatility after successful transsphenoidal surgery in women with microprolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Elevated prolactin levels in male youths treated with risperidone and quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

No association between bone mass and prolactin levels among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Olanzapine versus placebo in the treatment of adolescents with bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Elevation of prolactin levels by atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Dopamine antagonists and the development of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Elevated prolactin in pediatric patients on typical and atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

Sexual Dysfunction in First-Episode Schizophrenia Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881112442016

21 January 2018

Identifiers

DOI

10.1177/0269881112442016

1 reference

26 August 2017

1 reference